Cellebrite's stock gained 7.3% post-earnings, driven by ARR growth that met or exceeded guidance and the promising early adoption of its new AI product, Genesis, signaling potential upside beyond current revenue expectations.

• Annual Recurring Revenue (ARR) grew 21% year-over-year to $493 million, meeting or surpassing the high end of guidance.
• Adjusted EBITDA increased 29% year-over-year to $30.6 million.
• Free cash flow margin for the trailing 12 months remained strong at 32%.
• Genesis, the newly launched AI-enabled investigative analytics solution, has over 500 registered early users across 15 countries despite no marketing or pricing efforts.
• Early feedback from users highlights significant efficiencies and potential life-saving capabilities, suggesting upside to product penetration beyond 2026 plans, which currently assume zero AI-related revenue.